![The World Congress on Controversies in Obstetrics, Gynecology and Infertility (COGI). Click here to learn more.]({"type":"image" , "src" : "/sda/112382/JournalAd-COGI2024-Leaderboard.jpg"})
https://orcid.org/0000-0001-9773-2520
References
- Bray, F., et al., 2017. Cancer incidence in five continents, XI (electronic version). International Agency for Research on Cancer. Available from: https://ci5.iarc.fr/CI5-XI/Default.aspx [Accessed 14 Nov 2021].
- Cauley, J.A., 2003. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA, 290 (13), 1729–1738.
- Cushman, M., et al.,; Women’s Health Initiative Investigators. 2004. Estrogen plus progestin and risk of venous thrombosis. JAMA, 292 (13), 1573–1580.
- Głogowska-Szeląg, J., 2018. Assessment of the relationship between BMD and body mass index BMI in women with postmenopausal osteoporosis. Wiadomosci Lekarskie, 71 (9), 1714–1718. []. Polish.
- Jiang, H., et al., 2021. Loss of bone density and bone strength following premenopausal risk–reducing bilateral salpingo-oophorectomy: a prospective controlled study (WHAM Study. Osteoporosis International: a Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 32 (1), 101–112.
- Heiss, G., et al.,; WHI Investigators. 2008. Health risks and benefit 3 years after stopping randomized treatment with estrogen and progestin. JAMA, 299 (9), 1036–1045.
- LaCroix, A.Z., et al.,; WHI Investigators. 2011. Health outcomes after stopping conjugated equine esotrogens among postmenopausal women with prior hysterectomy. JAMA, 305 (13), 1305–1314.
- Lindsay, R., et al., 2002. Effect of lower doses of conjugated equine esrtogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA, 287 (20), 2668–2676.
- Mashiba, T., et al., 2017. Effects of suppressed bone remodeling by minodronic acid and alendronate on bone mass, microdamage accumulation, collagen crosslinks and bone mechanical properties in the lumbar vertebra of ovariectomized cynomolgus monkeys. Bone, 97, 184–191.
- Melton, L.J., et al., 2003. Fracture risk after bilateral oophorectomy in elderly women. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 18 (5), 900–905.
- Mori, H., et al., 2008. Minodronic acid (ONO-5920/YM529) prevents decrease in bone mineral density and bone strength, and improves bone microarchitecture in ovariectomized cynomolgus monkeys. Bone, 43 (5), 840–848.
- Nishizawa, Y., et al., 2013. Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition). Journal of Bone and Mineral Metabolism, 31 (1), 1–15.
- North American Menopause Society. 2010. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause, 17, 242–255.
- Okano, H., et al., 1998. The long-term effect of menopause on postmenopausal bone loss in Japanese women: results from a prospective study. Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 13 (2), 303–309.
- Orimo, H., et al., 2015. Guidelines for prevention and treatment of osteoporosis. Japanese. Available from: http://www.josteo.com/ja/guideline/doc/15_1.pdf [Accessed 10 Sep 2021].
- Riggs, B.L. and Melton, L. III., 1986. Involutional osteoporosis. The New England Journal of Medicine, 314 (26), 1676–1686.
- Rossouw, J.E., et al.,; Writing Group for the Women’s Health Initiative Investigators. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA, 288 (3), 321–333.
- Shi, L.F., Wu, Y. and Li, C.Y., 2016. Hormone therapy and risk of ovarian cancer in postmenopausal women: a systematic review and meta-analysis. Menopause, 23 (4), 417–424.
- Shimada, M., et al., 2006. Ovarian metastasis in carcinoma of the uterine cervix. Gynecologic Oncology, 101 (2), 234–237.
- Stuenkel, C.A., et al., 2015. Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology and Metabolism, 100 (11), 3975–4011.
- Tanishima, S., et al., 2013. A review of minodronic acid hydrate for the treatment of osteoporosis. Clinical Interventions in Aging, 8, 185–189.
- Vega, E.M., Egea, M.A. and Mautalen, C.A., 1994. Influence of the menopausal age on the severity of osteoporosis in women with vertebral fractures. Maturitas, 19 (2), 117–124.